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Abstract
Background: The blood saving effect of aprotinin has been well documented in cardiac surgery.
In thoracic surgery, very few recent studies, using rather high doses of aprotinin, have shown a
similar result. In a randomized prospective trial, we have tested the influence of aprotinin using an
ultra-low dose drug regime.
Methods: Fifty-nine patients, mean age 58 ± 13.25 years (mean ± SD) undergoing general thoracic
procedures were randomized into placebo (Group A) and treatment group (Group B). The group
B (n = 29) received 500.000 IU of aprotinin after induction to anesthesia and a repeat dose
immediately after chest closure. A detailed protocol with several laboratory parameters was
recorded. Patients were transfused when perioperative Ht was less than 26%.
Results: The two groups were similar in terms of age, gender, diagnosis, pathology, co-morbidity
and operations performed. The mean drainage of the first and second postoperative day in group
B was significantly reduced (412.6 ± 199.2 vs. 764.3 ± 213.9 ml, p < 0.000, and 248.3 ± 178.5 vs.
455.0 ± 274.6, p < 0.001). Similarly, the need for fresh frozen plasma transfusion was lower in group
B, p < 0.035. Both the operation time and the hospital stay were also less for group B but without
reaching statistical significance (84.6 ± 35.2 vs 101.2 ± 52.45 min. and 5.8 ± 1.6 vs 7.2 ± 3.6 days
respectively, p < 0.064). The overall transfusion rate did not differ significantly. No side effects of
aprotinin were noted.
Conclusion: The perioperative ultra-low dose aprotinin administration was associated with a
reduction of total blood losses and blood product requirements. We therefore consider the use
of aprotinin safe and effective in major thoracic surgery.
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Background
The incidence of postoperative hemorrhage after cardiop-
ulmonary bypass is about 5–7% and after pulmonary
resections is somewhat lower, about 4.6% [1,2]. Apro-
tinin is an antifibrinolytic agent, which is widely applied
during open-heart operations to reduce the postoperative
bleeding [3,4]. The high-cost of high-doses of aprotinin
used in cardiac surgery and some lack of definite useful-
ness in extracardiac operations make the thoracic sur-
geons hesitant to use it. In fact, its use in extracardiac
thoracic operations has so far only been tested in a few
studies [5-7]. It has been established that the perioperative
blood loss was significant reduced after infusion of 2 ×
106 units of aprotinin [5,6]. The aim of our study is to
evaluate if ultra-low dose of aprotinin (500.000 IU × 2),
has any potential beneficial effect on blood losses and
transfusion requirements as well as on the overall hospital
outcome after major thoracic operations.
Methods
Patient population and study criteria
Fifty-nine patients (53 males and 6 females) mean age
58.03 ± 13.25 years that underwent major thoracic opera-
tions were included in this randomized and placebo-con-
trolled study (table 1).
The preoperative exclusion criteria for enrollment in the
study were: 1) known blood coagulation disorders, 2)
known allergy to aprotinin (history of previous aprotinin
infusion), 3) pre-operative coagulation defects expressed
as PT or PTT > 1,5× control time or platelets count < 150
× 103/cm3, 4) pre-operative treatment with intravenous
heparin, coumarins, aspirin, or other anti-platelets factors
and 5) pre-operative serum creatinine level greater than
2.0 mg/lt.
The intra-operative exclusion criteria were: 1) massive
bleeding due to accidental injury to pulmonary artery or
vein, 2) emergency re-operation for bleeding and 3) mas-
sive transfusion for any other reason.
Table 1: Clinico-pathological parameters.
Group A Group B Total
Parameters Age 58.5 ± 9.8 57.5 ± 16.3 58.0 ± 13.2
Gender(male/females) 27/3 26/3 53/6
BMI* 25.2 ± 3.8 24.8 ± 3.9 25.0 ± 3.8
Diagnosis Bronchiectasis 1 1 2
Bullous disease 3 3 6
Diaphragmatic tumors 0 1 1
Empyema 4 4 8
Esophageal achalasia 1 0 1
Lung carcinoma 18 17 35
Pulmonary metastases 2 2 4
Thymoma 1 1 2
Total 30 29 59
Co-morbitidy COPD 7 6 13
Diabetes Mellitus 4 6 10
Hypertension 7 9 16
Serum Crea: 1.5–2.0 mg/dl 1 1 2
Past history of cancer 2 1 3
Coronary artery disease 3 3 6
Extracardiac arteriopathy 1 1 2
WBC's >15,000 mm/cm3 10 1
Pathology Primary lung carcinoma 18 17 35
Other organ carcinoma 3 4 7
Primary inflammatory disease 5 5 10
Other 4 3 7
Total 30 29 59
*BMI: Body Mass Index.
COPD = Chronic Obstructive Pulmonary Disease, WBC's = White Blood Count.Journal of Cardiothoracic Surgery 2008, 3:14 http://www.cardiothoracicsurgery.org/content/3/1/14
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Patients the morning before operation were randomly cat-
egorized by using relevant randomization tables, into pla-
cebo-group (Group A, n = 30) and aprotinin-treatment-
group (Group B, n = 29). Only the anesthetist knew
whether aprotinin was applied or not, thus, avoiding any
possible influence on hemostasis and coagulation by the
surgeons intraoperatively. The surgeons were informed
about randomization after the patient has been trans-
ferred to the ward. The study was approved by the hospital
ethics committee on human research and every patient
included signed the appropriate consent form.
Surgical procedures
All procedures were performed by the same surgical team.
The majority of the procedures were performed through a
lateral thoracotomy at the 5th intercostal space most often
for lung resection, except two medium sternotomies
(table 2). After pulmonary excision and meticulous
hemostasis, 1 or 2 chest-tubes 32 Fr were inserted, one to
the top (anteriorly) and the other to the base (posteri-
orly). Negative pressure suction of 20 cm H20 was utilized
electively and only if residual pneumothorax was present.
Drains were removed when no air leak was evident and
when the last 12 hour drainage-fluid was less than 100 ml
with the lung expanded. All patients received peri-opera-
tively subcutaneous prophylactic administration of low
molecular weight of tinzaparine sodium (Innohep®, Leo,
Denmark) 3.500 Anti-Xa IU/0.35 ML 2–4 hours preoper-
atively and 1 per day up to the day of discharge.
Aprotinin dosage
The patients in the aprotinin-group (Group B) received
immediately after intubation a test-dose of 1 ml solution
of aprotinin (Trasylol®, Bayer AG, Leverkusen, Germany)
followed by 500.000 IU of aprotinin intravenously in 50
ml of prepared manufactured solution administered over
a period of 15 minutes. The same dose was given to the
patient after thoracotomy closure. In contrast patients
belonging to the placebo-group (Group A) received 50 ml
of normal saline 0.9% solution before and after thoracot-
omy. No other haemostatic regiment was used. The intra-
operative blood losses were properly recorded and the
patient's vital signs were monitored. Intraoperatively or
while staying in the recovery area patients were transfused
with packed red blood cells (PRBC's) if Hb < 9 g/dl, while
postoperatively, transfusion was performed to those with
Hb < 8.5 g/dl. Fresh frozen plasma (FFP) was given on a
clinical basis if no obvious clots were observed at the end
of the procedure, or otherwise required because of clotting
screen disturbances.
Postoperative Care
The majority of patients (n = 50) underwent high thoracic
catheter epidural analgesia for the first 3 postoperative
days. The remaining received analgesia with intramuscu-
larly administered pethidine chloride. As a routine, only 3
doses of perioperative antibiotic prophylaxis with ticarcil-
lin & clavulanic acid 5.2 gr (Timentin® Injections, Glaxo-
SmithKline, UK) commencing prior to induction to
anesthesia, except of 6 patients in group A and 5 in group
B with inflammatory pathology, who received appropri-
ate antibiotic chemotherapy according to cultures. The
amount of postoperative drainage volumes were
recorded, as well as the hemoglobin level, the platelet
number, the WBC, the clotting profile and the creatinine
level, on the post-operative days 1st, 3rd, 5th and the 7th (for
those discharged after the 7th PO day) or at the day of dis-
charge when earlier.
Statistical analysis
All parametric values were expressed as mean measure-
ment ± Standard Deviation (SD) or as a number. At the
tables, the standard error of mean referred as SEM, mini-
mum as Min and maximum as Max. Comparisons of con-
tinuous normally distributed data among the groups were
performed by Student's t-test, p values < 0.05 were consid-
ered significant. When Shapiro-Wilk test of normality
revealed that data did not conform to a normal distribu-
tion, a non-parametric test was used. To evaluate the
groups in a nonparametric way, we used chi-square test
Table 2: Types of performed operations.
Group A Group B Total
Operation Wedge resection 2 2 4
Lobectomy 15 13 28
Bilobectomy 1 1 2
Pneumonectomy 3 4 7
Maximal thymectomy 1 1 2
Resection of diaphragmatic tumor 0 1 1
Decortication 4 4 8
Bullectomy 3 3 6
Esophageal myotomy 1 0 1
Total 30 29 59Journal of Cardiothoracic Surgery 2008, 3:14 http://www.cardiothoracicsurgery.org/content/3/1/14
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(nominal data) or the Mann-Whitney U  test (ordinal
data) and when the probability was p < 0.05, we consid-
ered the groups dissimilar. Analyses were performed using
SPSS for Windows, release 11.0.1 (SPSS Inc, Chicago, IL).
Results
The 2 groups were similar in terms of age, gender, diagno-
sis, pathology, co-morbidity and operation performed
(Tables 1, 2). There was no mortality and there was no sig-
nificant difference in morbidity. Major complications
included lung atelectasis due to sputum retention (n = 1,
Group A), acute respiratory failure requiring mechanical
ventilation (n = 1, Group B), prolonged air leak lasting
more than 10 days (n = 3, two patients for group A and
one for group B) and one case of atrial fibrillation (group
A). There was no reoperation for bleeding. The mean val-
ues of preoperative laboratory parameters are showing in
detail at the table 3. There was no statistical significant dif-
ference between the two groups for all of the parameters.
Post-operative blood loss and transfusion requirements
The mean post-operative blood loss during the 1st post-
operative day was 764.3 ± 213.9 ml in the placebo-group
and 412.6 ± 199.2 ml in the aprotinin-group (p = 0.001).
For the 2nd day the blood loss was 455.0 ± 274.6 ml in the
placebo group and 248.3 ± 178.5 ml in the aprotinin-
group (p = 0.001) (Table 4). The intraoperative transfu-
sion requirements in terms of PRBC's were similar in both
groups: 0.17 vs 0.17 PRBC's (p = 0.967). Similarly the
intraoperative need for fresh frozen plasma (FFP) transfu-
sion was almost the same in both groups 0.20 vs 0.21
units (p = 0.330) Postoperatively after the patient left the
recovery room up to the time of discharge, the need for
PRBC's transfusion was higher in the placebo-group, but
the difference was not significant: 0.03 vs 0.00 (p =
0.970). The post-operative transfusion of FFP was signifi-
cant higher in the placebo group: 0.87 Units vs 0.21 Units
(p = 0.035) (Table 5).
Postoperative Hematocrit and white blood cell count
The values of hematocrit at the 1st and 2nd postoperative
day and at discharge were all significantly higher in the
aprotinin-group: 35.9 vs 33.0, 34.5 vs 32.1 and 35.0 vs
32.0 (p = 0.07, 0.026, and 0.035 respectively) (Table 6).
There was no difference between the two groups in the
preoperative white blood count (WBC) (p = 0.313). How-
ever, there was a considerable elevation in both groups
during the two first postoperative days, more marked in
the group A, but not statistically significant. At the 7th day
(for those discharged after the 7th day) the WBC was sig-
nificantly preserved for group B (8614.3 ± 2328.9 vs
13168.2 ± 3497.4) (p = 0.001) (Table 7).
Operation time and Postoperative hospital stay
The operation-time was lower in the aprotinin-group but
the difference was not significant: 84.66 ± 35.23 min vs
101.17 ± 52.45 min (p = 0.161). However, the postopera-
tive hospital-stay was longer in the placebo-group, but
without reaching statistical significance (7.2 ± 3.61 days
vs 5.83 ± 1.65 days) (p = 0.064) (Table 8).
Discussion
Aprotinin is generally regarded as an effective hemostatic
agent that preserves platelet function thus leading to post-
operative blood loss reduction.
Table 3: Preoperative Laboratory data
Parameters Group A† Group B† Total†
Ht 40.69 ± 0.80 41.27 ± 0.65 40.98 ± 0.51
WBC 8,821.00 ± 498.54 8,170.00 ± 400.25 8,501.02 ± 320.98
PLT 260,200 ± 15,850 302,414 ± 24,537 280,949 ± 14,643
PT 13.39 ± 0.41 12.57 ± 0.24 12.99 ± 0.25
PTT 33.8 ± 0.90 33.83 ± 1.25 33.6 ± 0.76
INR 1.06 ± 0.04 1.01 ± 0.02 1.04 ± 0.02
Fibrinogen 496.97 ± 24.63 471.28 ± 26.55 484.34 ± 18.01
D-dimers 0.84 ± 0.18 0.84 ± 0.21 0.84 ± 0.14
Urea 38.13 ± 2.15 37.76 ± 3.03 37.95 ± 1.83
Crea 0.94 ± 0.04 0.98 ± 0.05 0.96 ± 0.03
SGOT 21.13 ± 1.60 27.52 ± 3.05 24.27 ± 1.74
SGPT 29.33 ± 8.22 37.93 ± 6.84 33.56 ± 5.35
Total Protein 7.27 ± 0.10 7.36 ± 0.14 7.31 ± 0.08
Albumin 4.00 ± 0.10 4.16 ± 0.13 4.07 ± 0.8
Total Bil 0.61 ± 0.09 0.63 ± 0.06 0.62 ± 0.05
Direct Bil 0.11 ± 0.02 0.12 ± 0.01 0.11 ± 0.01
†values are express in terms of Mean ± SEM (SEM denotes Standard Error of Mean).
Ht = Hematocrit, WBC = white blood count, PLT = Platelets, PT = Prothrombin time, PTT = Partial thromboplastin time, INR = international 
normalized ratio, Creat = Creatinine, SGOT = serum glutamic oxaloacetate transaminase, SGPT = serum glutamic pyruvic transaminase, Bil = 
BilirubinJournal of Cardiothoracic Surgery 2008, 3:14 http://www.cardiothoracicsurgery.org/content/3/1/14
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Aprotinin was discovered in 1930, but it was clinically
applied much later, in the early 1960s for the treatment of
acute pancreatitis. It's a protease inhibitor that exerts its
effect at different sites in the inflammatory cascade. In par-
ticular, aprotinin inhibits the activity of kallikrein, which
consequently decreases the activation of complement and
bradykinin [8]. Due to this action aprotinin is widely
applied in cardiac operations using cardiopulmonary
bypass [3,4]. During these operations, the extracorporeal
circulation activates kallikrein, which liberates factor XII,
complement, plasmin and bradykinin. All these increase
the inflammatory injury, the capillary permeability and
coagulation abnormalities and represent sub-bases of the
systemic inflammatory response syndrome (SIRS) [3,8].
In a recent systematic review and meta-analysis of rand-
omized clinical trials, Sedrakyan et al. [9] evaluated the
effect of aprotinin on 3878 patients undergoing coronary
surgery and found that not only it reduces the transfusion
n e e d s ,  b u t  a l s o  i t  i s  a s s o c i a t e d  w i t h  n o  p o s t - o p e r a t i v e
complications and therefore its use could be expanded
into coronary surgery with no reluctance. In fact there was
a tendency toward reduction of atrial fibrillation occur-
rence in those who received aprotinin. Dignan et al. using
an ultra-low dose of aprotinin (500.000 × 2 KIU) reported
a beneficial effect and supported its routine use in coro-
nary surgery [10].
Since the introduction of aprotinin in clinical practice, it
has also been used in other types of surgery where benefi-
Table 4: Post-operative blood loss.
Parameters Value Group A Group B p
Day 1 Postoperative Thoracic Drainage (ml) Mean 764.3 412.6 0.000
Min 350.0 150.0
Max 1230.0 900.0
SEM 39.1 37.0
SD 213.9 199.2
Day 1 Postoperative Thoracic Drainage (ml) Mean 455.0 248.3 0.001
Min .0 .0
Max 1100.0 700.0
SEM 50.1 33.2
SD 274.6 178.5
Post operative blood loss. Mean post-operative blood loss at 1st and 2nd postoperative day. SD = Standard deviation, Min = minimal, Max = 
maximal, SEM = Standard Error of Mean.
Table 5: Transfusion requirements
Parameters Value Group A Group B p
Intraoperative PRBC's Units Mean 0.17 0.17 0.967
SD 0.531 0.539
Min 0 0
Max 2 2
Postoperative PRBC's Units Mean 0.03 0.00 0.970
SD 0.183 0.000
Min 0 0
Max 1 0
Intraoperative FFP's Units Mean 0.20 0.21 0.330
SD 0.761 0.620
Min 0 0
Max 3 2
Postoperative FFP's Units Mean 0.87 0.21 0.035
SD 1.525 0.620
Min 0 0
Max 4 2
Intraoperative and post-operative transfusion requirements. PRBC's = Packed Red Blood Cells. FFP's = Fresh Frozen Plasma.Journal of Cardiothoracic Surgery 2008, 3:14 http://www.cardiothoracicsurgery.org/content/3/1/14
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cial effects were expected. There have been some reports
which have demonstrated that the use of aprotinin is
effective in reducing the need of blood transfusion after
liver transplantation [11] and major orthopedic surgery
[12].
In thoracic surgery and particularly in high risk patients
where severe post-operative bleeding is often anticipated,
use of aprotinin has been similarly tested in clinical trials.
Bedirhan et al. [6], in a randomized trial using 106 kal-
likrein inhibitory units (KIU) at the beginning and fol-
lowed by an infusion of the same dose during chest
closure, showed that transfusion requirements and post-
operative bleeding was reduced. Kyriss et al. [5], in a pla-
cebo-controlled randomized phase IV study, evaluated
the effect of aprotinin in thoracic surgical operations.
They initially infused 2 × 106 KIU followed by 5 × 105
KIU/hr during surgery. They similarly reported a reduc-
tion in both perioperative blood loss and blood transfu-
sion.
Major thoracic surgery is associated with a considerable
risk of bleeding. For pulmonary excisions this risk is about
4.6% [2] and re-exploration thoracotomy for hemorrhage
is required in 3.7% [13]. Furthermore, SIRS may arise as a
result not only following open-heart operations but also
after a major trauma or a major operation [14]. The bene-
ficial effect of aprotinin, namely inhibition of contact acti-
vation and fibrinolysis while preserving platelet function
has not been tested so far in clinical trials using rather
lower doses as in the present study. Regarding post-oper-
Table 6: Hematocrit values.
Parameters Value Group A Group B p
Preoperative Hematocrit Mean 40.7 41.3 0.573
Min 28.2 35.5
Max 48.0 50.2
SEM 0.8 0.6
SD 4.4 3.5
Day 1 Postoperative Hematocrit Mean 33.0 35.9 0.007
Min 25.7 28.0
Max 42.8 44.9
SEM 0.7 0.7
SD 4.1 3.9
Day 2 Postoperative Hematocrit Mean 32.1 34.5 0.026
Min 24.2 25.7
Max 39.0 41.8
SEM 0.7 0.7
SD 4.1 3.9
Discharge Hematocrit Mean 32.0 35.0 0.035
Min 26.7 24.3
Max 39.0 43.5
SEM 1.3 1.3
SD 4.1 4.7
Hematocrit values at the 1st, 2nd postoperative day and at discharge.
Table 7: Perioperative White Blood Count values.
Parameters Value Group A Group B p
Preoperative WBC Mean 8,821.0 8,170.0 0.313
SD 2,730.6 2,155.4
Min 4,970.0 3,900.0
Max 16,300.0 13,710.0
Day 1 Postoperative WBC Mean 11,564.7 10,470.0 0.296
SD 4,822.2 2,869.7
Min 5,840.0 5,820.0
Max 28,700.0 16,890.0
Day 2 Postoperative WBC Mean 10,644.3 9,610.7 0.223
SD 3,494.1 2,832.5
Min 5,550.0 5,000.0
Max 17,710.0 16,490.0
Day 7 Postoperative WBC Mean 13,168.2 8,614.3 0.001
SD 3,497.4 2,328.9
Min 7,600.0 5,260.0
Max 18,350.0 14,400.0
White blood count values at 1st, 2nd and at 7th postoperative day 
(for those patients discharged after the 7th PO day (WBC = White 
Blood Count).Journal of Cardiothoracic Surgery 2008, 3:14 http://www.cardiothoracicsurgery.org/content/3/1/14
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ative blood loss, we demonstrated that this was signifi-
cantly higher for the placebo-group: 764.3 ± 213.9 ml vs
412.6 ± 199.2 ml and 455.0 ± 274.6 ml vs 284.3 ± 178 ml
for the first end second postoperative days comparing to
the aprotinin-group (p = 0,001) (Table 4). This higher
blood loss may explain the significant difference in the
hematocrit level in favor of group B during postoperative
period (Table 6). We have also showed that there was no
significant difference between the two groups concerning
the blood transfusion requirements, either intraopera-
tively or postoperatively (Table 5). In our opinion, these
differences are attributed to three reasons: a) the patients
with perioperative massive surgical bleeding were
excluded from the study, b) our postoperative transfusion
criteria were very strict and we avoided transfusing
patients with hemoglobin higher of 8.5 g/dl. This is very
important guideline for transfusing patients in thoracic
surgery as it has been previously reported by our group
[15]. And c) we are not reluctant in transfusing FFP's if
there is a bleeding tendency and severe oozing with no
clot formation, even on a clinical ground. As a result, the
amount of post operative transfused FFP's was significant
higher in the placebo-group (0.87 Units vs 0.21 Units for
the aprotinin-group), (p = 0.035) (Table 5). This relation
itself represents an indirect evidence of prevailing hemor-
rhagic diathesis of patients in placebo-group.
We also observed postoperative preservation on the
number of leukocytes in the aprotinin-group in contrast
to the placebo-group. This finding is attributed to the anti-
inflammatory action of aprotinin. There is evidence that
aprotinin modifies the inflammatory response through an
inhibition of neutrophil activation [16]. It has already
been confirmed, the reduced ability of leukocytes to
attach along the vessel wall, to firm adhesion and to trans-
migrate into the extravascular space under the influence of
aprotinin [17,18]. Furthermore, Asimakopoulos et al.
showed experimentally that infusion of aprotinin inhibits
significantly the leukocyte extravasation [14].
An unexpected finding from our study was the difference
in operating time between the groups. In the placebo-
group the average operating time was 101.17 ± 52.5 min,
while in the aprotinin-group was only 84.6 ± 35.23 min.
Although it was not statistically significant, there was ten-
dency to be so (Table 8). This difference reflected the addi-
tional time demanded for appropriate intraoperative
hemostasis.
Another remarkable result of our study was the lower
postoperative hospital stay observed in the aprotinin-
group (7.2 ± 3.6 days for the placebo-group vs. 5.83 ± 1.65
days for the aprotinin-group). This difference, which has
an obvious tendency to be significant in favor of aprotinin
usage, (p = 0,064) (Table 8) was related to the lower inci-
dence of bleeding in the aprotinin-group on the one
hand, and to the anti-inflammatory activity of aprotinin
as already mentioned, including the preservation of the
WBC during postoperative course.
There are two main disadvantages of aprotinin, namely,
the possibility of eliciting allergic reactions and the high
cost. The allergic adverse effects are rare, less than
0.1–0.2% [3,19]. In our study, no allergic reactions were
observed. In terms of cost, the usual dose of aprotinin in
extracardiac operations ranges between 2 × 106 to 2.5 ×
106 Units with an average cost between 48 to 60 € (Patras,
Greece). In our study, using a total of 106 KIU, the total
cost per patient per operation was 24 €, which we believe
it is definitely cost beneficial. Nevertheless, any cost of
aprotinin is compensated by that of potential transfusion
of blood and its products, and possibly by that of a longer
operation time and hospital stay [20].
Table 8: Operation time and postoperative stay.
Parameters Value Group A Group B p
Operation Time (min) Mean 101.17 84.66 0.161
Min 40.00 40.00
Max 270.00 180.00
SEM 9.58 6.54
SD 52.45 35.25
Postoperative Hospital stay (days) Mean 7.20 5.83 0.064
Min 4.00 3.00
Max 21.00 10.00
SEM 0.66 0.31
SD 3.61 1.65
The operation-time and postoperative stay were lower in the aprotinin-group reaching statistical significance.Publish with BioMed Central    and   every 
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Conclusion
In summary, the ultra-low dose of aprotinin tested in this
study was associated with a reduction of total blood losses
and blood product requirements as well as with lower
intraoperative time and overall hospital stay. We therefore
consider the use of aprotinin safe and recommend its use
in thoracic surgery and in particular, when potential peri-
operative bleeding is anticipated.
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